GlassScriptPhysician profile
Ashley B Baxley
NPI 1023852159
$1,868.59
in general payments reported to CMS, 2019-2025
25 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $556 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $235.92 | 2024-2025 | Rexulti |
| Corcept Therapeutics | $187.13 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $178.77 | 2024-2025 | |
| Abbvie INC. | $171.72 | 2024-2025 | |
| Novo Nordisk INC | $168.83 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $158.64 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $95.33 | 2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $70.52 | 2024 | Xelstrym |
| Lilly USA, LLC | $64.10 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $61.51 | 2025 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $54.76 | 2024-2025 | Spravato |
| Boston Scientific Corporation | $51.98 | 2024 | Spectra Wavewriter, Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $46.71 | 2025 | Gemtesa |
| Antares Pharma, INC. | $46.46 | 2024-2025 | Xyosted |
| Abbott Laboratories | $46.38 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $38.64 | 2025 | Rexulti |
| Astellas Pharma US INC | $34.37 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $33.00 | 2025 | |
| Daiichi Sankyo INC. | $29.84 | 2024 | Injectafer |
| Stryker Corporation | $21.93 | 2025 | Clottriever Bold Catheter |
| Axsome Therapeutics, INC. | $16.15 | 2025 | Sunosi |
| Teleflex LLC | $15.25 | 2024 | Urolift |
| Phathom Pharmaceuticals, INC. | $13.67 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.59 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.39 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Baxley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.